{"protocolSection":{"identificationModule":{"nctId":"NCT01929096","orgStudyIdInfo":{"id":"SIM-23-01"},"organization":{"fullName":"Jiangsu Simcere Pharmaceutical Co., Ltd.","class":"INDUSTRY"},"briefTitle":"Compound Edaravone Injection for Acute Ischemic Stroke","officialTitle":"Compound Edaravone Injection for Acute Ischemic Stroke, a Multi-center, Randomized, Double-blind, Multi-dose, Parallel, and Controlled Phase II Trial"},"statusModule":{"statusVerifiedDate":"2015-07","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2013-08"},"primaryCompletionDateStruct":{"date":"2014-12","type":"ACTUAL"},"completionDateStruct":{"date":"2015-02","type":"ACTUAL"},"studyFirstSubmitDate":"2013-08-22","studyFirstSubmitQcDate":"2013-08-22","studyFirstPostDateStruct":{"date":"2013-08-27","type":"ESTIMATED"},"lastUpdateSubmitDate":"2015-07-01","lastUpdatePostDateStruct":{"date":"2015-07-03","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Jiangsu Simcere Pharmaceutical Co., Ltd.","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false},"descriptionModule":{"briefSummary":"1. To investigate the efficacy and safety of multi-doses Compound Edaravone Injection versus Edaravone Injection for acute ischemic stroke patients;\n2. To provide evidence for the design of Compound Edaravone Injection Phase III trial."},"conditionsModule":{"conditions":["Acute Ischemic Stroke"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"QUADRUPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":400,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Low-dose group","type":"EXPERIMENTAL","description":"Compound Edaravone Injection, 12.5mg/dose (Edaravone 10mg, (+)-Borneol 2.5mg), one dose every 12 hours, continue for 14 days","interventionNames":["Drug: Compound Edaravone Injection"]},{"label":"Medium-dose group","type":"EXPERIMENTAL","description":"Compound Edaravone Injection, 37.5mg/dose (Edaravone 30mg, (+)-Borneol 7.5mg), one dose every 12 hours, continue for 14 days","interventionNames":["Drug: Compound Edaravone Injection"]},{"label":"High-dose group","type":"EXPERIMENTAL","description":"Compound Edaravone Injection, 62.5mg/dose (Edaravone 50mg, (+)-Borneol 12.5mg), one dose every 12 hours, continue for 14 days","interventionNames":["Drug: Compound Edaravone Injection"]},{"label":"Control group","type":"ACTIVE_COMPARATOR","description":"Edaravone Injection，30 mg/dose, one dose every 12 hours, continues for 14 days","interventionNames":["Drug: Edaravone Injection"]}],"interventions":[{"type":"DRUG","name":"Compound Edaravone Injection","armGroupLabels":["High-dose group","Low-dose group","Medium-dose group"]},{"type":"DRUG","name":"Edaravone Injection","armGroupLabels":["Control group"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"mRS score on day 90","timeFrame":"day 90"},{"measure":"Change from baseline NIHSS score on day 14","timeFrame":"day 14"}],"secondaryOutcomes":[{"measure":"The proportion of patients with NIHSS score 0-1 (including motor function) on day 14, 30, 90","timeFrame":"day 14, 30, 90"},{"measure":"The proportion of patients with Barthel Index (BI) score greater than or equal to 95 on day 14, 30, 90","timeFrame":"day 14, 30, 90"},{"measure":"The Montreal Cognitive Assessment(MoCA) score on day 14, 30, 90","timeFrame":"day 14, 30, 90"},{"measure":"Stroke Impact Scale (SIS) score on day 90","timeFrame":"day 90"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Hospitalized patients, diagnosed of ischemic stroke;\n* Onset of stroke is less than or equal to 48 hours;\n* There are clear signs of neurological deficit: 4≤NIHSS score≤24, and also, the sum of NIHSS score for the upper limb and the lower limb is greater than or equal to 2;\n* Patients signed written inform consent.\n\nExclusion Criteria:\n\n* Cranial CT scan finds intracranial bleeding disorders: hemorrhagic stroke, epidural hematoma, intracranial hematoma, intraventricular hemorrhage, subarachnoid hemorrhage;\n* Iatrogenic stroke;\n* Severe disturbance of consciousness: NIHSS category 1a for consciousness is greater than 1；\n* The mRS score prior to this onset is greater than 1;\n* Transient ischemic attack (TIA);\n* SBP after blood pressure control is still greater than to equal to 220 mmHg, or DBP after blood pressure control is still greater than or equal to 120 mmHg;\n* Patients with severe mental disorders and dementia;\n* ALT or AST is greater than 2.0×ULN or previously known liver diseases, such as acute hepatitis, chronic active hepatitis, liver cirrhosis;\n* Creatinine clearance is less than 30 ml/min or previously known severe renal diseases;\n* Therapeutic neuroprotective agents have been applied after onset, including commercially available edaravone, nimodipine, ganglioside, citicoline, piracetam, butyl benzene peptides, Urinary Kallidinogenase;\n* Arterial or venous thrombolytic therapy has been applied after onset;\n* With malignant tumors or receiving concurrent antitumor treatment;\n* With severe systemic disease, life expectancy is less than 90 days;\n* Pregnant or lactating women;\n* Participate in other clinical studies within 30 days before randomization;\n* The investigators consider the patients are not suitable for this trial.","healthyVolunteers":false,"sex":"ALL","minimumAge":"35 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Yongjun Wang, MD","affiliation":"Beijing Tiantan Hospital","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"Navy General Hospital of The Chinese PLA","city":"Beijing","state":"Beijing","zip":"100048","country":"China","geoPoint":{"lat":39.9075,"lon":116.39723}},{"facility":"Beijing Tiantan Hospital affiliated to Capital Medical University","city":"Beijing","state":"Beijing","zip":"100050","country":"China","geoPoint":{"lat":39.9075,"lon":116.39723}},{"facility":"Peking University Third Hospital","city":"Beijing","state":"Beijing","zip":"100191","country":"China","geoPoint":{"lat":39.9075,"lon":116.39723}},{"facility":"The First Affiliated Hospital of Chongqing Medical University","city":"Chongqing","state":"Chongqing","zip":"400010","country":"China","geoPoint":{"lat":29.56278,"lon":106.55278}},{"facility":"The First Affiliated Hospital of Third Military Medical University of Chinese PLA","city":"Chongqing","state":"Chongqing","zip":"400038","country":"China","geoPoint":{"lat":29.56278,"lon":106.55278}},{"facility":"The First Affiliated Hospital of Sun Yat-sen University","city":"Guangzhou","state":"Guangdong","zip":"510080","country":"China","geoPoint":{"lat":23.11667,"lon":113.25}},{"facility":"Peking University Shenzhen Hospital","city":"Shenzhen","state":"Guangdong","zip":"518036","country":"China","geoPoint":{"lat":22.54554,"lon":114.0683}},{"facility":"The Second Hospital of Hebei Medical University","city":"Shijiazhuang","state":"Hebei","zip":"050000","country":"China","geoPoint":{"lat":38.04139,"lon":114.47861}},{"facility":"Hebei General Hospital","city":"Shijiazhuang","state":"Hebei","zip":"050051","country":"China","geoPoint":{"lat":38.04139,"lon":114.47861}},{"facility":"The Second Affiliated Hospital of Haerbin Medical University","city":"Haerbin","state":"Heilongjiang","zip":"150001","country":"China","geoPoint":{"lat":31.8696,"lon":101.742}},{"facility":"Hunan Provincial People's Hospital","city":"Changsha","state":"Hunan","zip":"410005","country":"China","geoPoint":{"lat":28.19874,"lon":112.97087}},{"facility":"Central Hospital of Baotou","city":"Baotou","state":"Inner Mongolia","zip":"014040","country":"China","geoPoint":{"lat":40.65222,"lon":109.82222}},{"facility":"Nanjing First Hospital","city":"Nanjing","state":"Jiangsu","zip":"210006","country":"China","geoPoint":{"lat":32.06167,"lon":118.77778}},{"facility":"The Second Affiliated Hospital of Nanjing Medical University","city":"Nanjing","state":"Jiangsu","zip":"210011","country":"China","geoPoint":{"lat":32.06167,"lon":118.77778}},{"facility":"Nanjing Brain Hospital","city":"Nanjing","state":"Jiangsu","zip":"210029","country":"China","geoPoint":{"lat":32.06167,"lon":118.77778}},{"facility":"The Affiliated Hospital of Xuzhou Medical College","city":"Xuzhou","state":"Jiangsu","zip":"221006","country":"China","geoPoint":{"lat":34.18045,"lon":117.15707}},{"facility":"Jiangxi Provincial People's Hospital","city":"Nanchang","state":"Jiangxi","zip":"330006","country":"China","geoPoint":{"lat":28.68396,"lon":115.85306}},{"facility":"The General Hospital of Shenyang Military, Chinese PLA","city":"Shenyang","state":"Liaoning","zip":"110016","country":"China","geoPoint":{"lat":41.79222,"lon":123.43278}},{"facility":"Qilu Hospital of Shandong University","city":"Jinan","state":"Shandong","zip":"250012","country":"China","geoPoint":{"lat":36.66833,"lon":116.99722}},{"facility":"The Second Hospital of Shandong University","city":"Jinan","state":"Shandong","zip":"250033","country":"China","geoPoint":{"lat":36.66833,"lon":116.99722}},{"facility":"Qingdao Municipal Hospital","city":"Qingdao","state":"Shandong","zip":"266011","country":"China","geoPoint":{"lat":36.06488,"lon":120.38042}},{"facility":"Shanghai Changzheng Hospital","city":"Shanghai","state":"Shanghai","zip":"200003","country":"China","geoPoint":{"lat":31.22222,"lon":121.45806}},{"facility":"Rui Jin Hospital Shanghai Jiao Tong University School of Medicine","city":"Shanghai","state":"Shanghai","zip":"200025","country":"China","geoPoint":{"lat":31.22222,"lon":121.45806}},{"facility":"The First Affiliated Hospital of Shanxi Medical University","city":"Taiyuan","state":"Shanxi","zip":"030001","country":"China","geoPoint":{"lat":37.86944,"lon":112.56028}},{"facility":"The Second Affiliated Hospital of Shanxi Medical University","city":"Taiyuan","state":"Shanxi","zip":"030001","country":"China","geoPoint":{"lat":37.86944,"lon":112.56028}},{"facility":"Tianjin People's Hospital","city":"Tianjin","state":"Tianjin","zip":"300000","country":"China","geoPoint":{"lat":39.14222,"lon":117.17667}},{"facility":"Tianjin Medical University General Hospital","city":"Tianjin","state":"Tianjin","zip":"300052","country":"China","geoPoint":{"lat":39.14222,"lon":117.17667}},{"facility":"Tianjin Huanhu Hospital","city":"Tianjin","state":"Tianjin","zip":"300060","country":"China","geoPoint":{"lat":39.14222,"lon":117.17667}}]},"referencesModule":{"references":[{"pmid":"31709115","type":"DERIVED","citation":"Xu J, Wang Y, Wang A, Gao Z, Gao X, Chen H, Zhou J, Zhao X, Wang Y. Safety and efficacy of Edaravone Dexborneol versus edaravone for patients with acute ischaemic stroke: a phase II, multicentre, randomised, double-blind, multiple-dose, active-controlled clinical trial. Stroke Vasc Neurol. 2019 Apr 22;4(3):109-114. doi: 10.1136/svn-2018-000221. eCollection 2019 Sep."}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000020521","term":"Stroke"},{"id":"D000083242","term":"Ischemic Stroke"},{"id":"D000002544","term":"Cerebral Infarction"},{"id":"D000007511","term":"Ischemia"}],"ancestors":[{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000010335","term":"Pathologic Processes"},{"id":"D000020520","term":"Brain Infarction"},{"id":"D000002545","term":"Brain Ischemia"},{"id":"D000007238","term":"Infarction"},{"id":"D000009336","term":"Necrosis"}],"browseLeaves":[{"id":"M21996","name":"Stroke","asFound":"Stroke","relevance":"HIGH"},{"id":"M10233","name":"Ischemia","asFound":"Ischemic","relevance":"HIGH"},{"id":"M2401","name":"Ischemic Stroke","asFound":"Ischemic Stroke","relevance":"HIGH"},{"id":"M9972","name":"Infarction","relevance":"LOW"},{"id":"M5483","name":"Cerebral Infarction","asFound":"Ischemic Stroke","relevance":"HIGH"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"M21995","name":"Brain Infarction","relevance":"LOW"},{"id":"M5484","name":"Brain Ischemia","relevance":"LOW"},{"id":"M11974","name":"Necrosis","relevance":"LOW"},{"id":"T170","name":"Acute Graft Versus Host Disease","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"Rare","name":"Rare Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000077553","term":"Edaravone"}],"ancestors":[{"id":"D000016166","term":"Free Radical Scavengers"},{"id":"D000000975","term":"Antioxidants"},{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"},{"id":"D000018696","term":"Neuroprotective Agents"},{"id":"D000020011","term":"Protective Agents"},{"id":"D000045505","term":"Physiological Effects of Drugs"}],"browseLeaves":[{"id":"M1831","name":"Edaravone","asFound":"Lay","relevance":"HIGH"},{"id":"M3982","name":"Antioxidants","relevance":"LOW"},{"id":"M20463","name":"Neuroprotective Agents","relevance":"LOW"},{"id":"M21559","name":"Protective Agents","relevance":"LOW"}],"browseBranches":[{"abbrev":"NeuroAg","name":"Neuroprotective Agents"},{"abbrev":"All","name":"All Drugs and Chemicals"}]}},"hasResults":false}